

Supplemental Data

Risk and outcome of secondary primary malignancies after radioactive iodine treatment in differentiated thyroid cancer patients

Xiaoran Mei, Xiaoqin Yao, Fang Feng, Weiwei Cheng, Hui Wang




Figure S1. The spectrum of SPMs in patients treated with and without RAI.

	Incidence in all DTC survivors	Number of patients, n(%)	
		+RAI	-RAI
All cancer combined	4.4%	2289	2339
Oral Cavity and Pharynx	0.1%	56(2.4%)	51(2.2%)
Digestive System	0.6%	319(13.9%)	356(15.2%)
Respiratory System	0.5%	247(10.8%)	254(10.9%)
Skin	0.3%	138(6.0%)	137(5.9%)
Breast	1.1%	547(23.9%)	574(24.5%)
Female Genital System	0.4%	179(7.8%)	206(8.8%)
Male Genital System	0.5%	237(10.4%)	233(10.0%)
Urinary System	0.4%	194(8.5%)	191(8.2%)
Nervous System	0.1%	30(1.3%)	36(1.5%)
Hematologic System	0.5%	261(11.4%)	215(9.2%)

Table S1. The incidence of SPMs in all DTC survivors and the proportion of each system of SPMs by their site.

	Crude RR (95% CI)	<i>P value</i>
All cancer combined	1.01(0.95-1.07)	<i>0.749</i>
Oral Cavity and Pharynx	1.13(0.78-1.66)	<i>0.520</i>
Digestive System	0.92(0.79-1.08)	<i>0.310</i>
Respiratory System	1.00(0.84-1.20)	<i>0.971</i>
Skin	1.04(0.82-1.31)	<i>0.750</i>
Breast	0.98(0.87-1.11)	<i>0.778</i>
Female Genital System	0.90(0.73-1.10)	<i>0.286</i>
Male Genital System	1.05(0.88-1.26)	<i>0.602</i>
Urinary System	1.05(0.86-1.28)	<i>0.647</i>
Nervous System	0.86(0.53-1.40)	<i>0.541</i>
Hematologic System	1.25(1.05-1.50)	<i>0.015</i>

Table S2. The crude relative risk of SPMs associated with RAI treatment by the site of SPMs.